591 related articles for article (PubMed ID: 9538138)
1. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma--results of a multiparametric study.
Bevilacqua P; Barbareschi M; Verderio P; Boracchi P; Caffo O; Dalla Palma P; Meli S; Weidner N; Gasparini G
Breast Cancer Res Treat; 1995; 36(2):205-17. PubMed ID: 8534868
[TBL] [Abstract][Full Text] [Related]
3. 67-kDa laminin-receptor expression adds prognostic information to intra-tumoral microvessel density in node-negative breast cancer.
Gasparini G; Barbareschi M; Boracchi P; Bevilacqua P; Verderio P; Dalla Palma P; Ménard S
Int J Cancer; 1995 Mar; 60(5):604-10. PubMed ID: 7860133
[TBL] [Abstract][Full Text] [Related]
4. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients.
Gasparini G; Fox SB; Verderio P; Bonoldi E; Bevilacqua P; Boracchi P; Dante S; Marubini E; Harris AL
Clin Cancer Res; 1996 Jul; 2(7):1191-8. PubMed ID: 9816287
[TBL] [Abstract][Full Text] [Related]
5. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
6. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.
Gasparini G; Weidner N; Bevilacqua P; Maluta S; Dalla Palma P; Caffo O; Barbareschi M; Boracchi P; Marubini E; Pozza F
J Clin Oncol; 1994 Mar; 12(3):454-66. PubMed ID: 7509851
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy.
Pelosio P; Barbareschi M; Bonoldi E; Marchetti A; Verderio P; Caffo O; Bevilacqua P; Boracchi P; Buttitta F; Barbazza R; Dalla Palma P; Gasparini G
Ann Oncol; 1996 Sep; 7(7):695-703. PubMed ID: 8905027
[TBL] [Abstract][Full Text] [Related]
10. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
[TBL] [Abstract][Full Text] [Related]
11. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
[TBL] [Abstract][Full Text] [Related]
12. Tumor angiogenesis in node-negative breast carcinomas--relationship with epidermal growth factor receptor, estrogen receptor, and survival.
Fox SB; Leek RD; Smith K; Hollyer J; Greenall M; Harris AL
Breast Cancer Res Treat; 1994 Jan; 29(1):109-16. PubMed ID: 7517221
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
[TBL] [Abstract][Full Text] [Related]
14. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer.
Thorpe SM; Rose C; Rasmussen BB; Mouridsen HT; Bayer T; Keiding N
Cancer Res; 1987 Nov; 47(22):6126-33. PubMed ID: 3664512
[TBL] [Abstract][Full Text] [Related]
17. Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients.
Levesque MA; Katsaros D; Yu H; Giai M; Genta F; Roagna R; Ponzone R; Massobrio M; Sismondi P; Diamandis EP
Int J Cancer; 1998 Apr; 79(2):147-52. PubMed ID: 9583729
[TBL] [Abstract][Full Text] [Related]
18. Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients.
Gago FE; Tello OM; Diblasi AM; Ciocca DR
J Steroid Biochem Mol Biol; 1998 Dec; 67(5-6):431-7. PubMed ID: 10030692
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
20. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]